Commission Delegated Regulation (EU) 2021/849 of 11 March 2021 amending, for the purposes of its adaptation to technical and scientific progress, Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixturesText with EEA relevance.

Commission Delegated Regulation (EU) 2021/849 of 11 March 2021 amending, for the purposes of its adaptation to technical and scientific progress, Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance) THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning of the European Union, Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 OJ L 353, 31.12.2008, p. 1. , and in particular Article 37(5) thereof, Whereas: (1) Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation. (2) Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (Agency) pursuant to Article 37 of Regulation (EC) No 1272/2008. The Committee for Risk Assessment of the Agency (RAC) adopted opinions The opinions are accessible via the following website:https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/ on those proposals, after having taken account of the comments received from the parties concerned. Those RAC opinions are: Opinion of 15 March 2019 concerning 1,2,4-triazole, Opinion of 15 March 2019 concerning 1,4-dioxane, Opinion of 15 March 2019 concerning benzyl salicylate, Opinion of 15 March 2019 concerning flumioxazin (ISO), Opinion of 15 March 2019 concerning mancozeb (ISO), Opinion of 15 March 2019 concerning M-factors for long-term aquatic hazard for the copper substances listed in Commission Regulation (EU) 2016/1179, Opinion of 15 March 2019 concerning N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane, Opinion of 15 March 2019 concerning N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen, Opinion of 15 March 2019 concerning p-cymene; 1-isopropyl-4-methylbenzene, Opinion of 15 March 2019 concerning p-mentha-1,3-diene; alpha-terpinene; 1-isopropyl-4-methylcyclohexa-1,3-diene, Opinion of 15 March 2019 concerning prothioconazole, Opinion of 15 March 2019 concerning (R)-p-mentha-1,8-diene; d-limonene,

Opinion of 15 March 2019 concerning thiophanate-methyl, Opinion of 15 March 2019 concerning tolclofos-methyl (ISO); O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate, Opinion of 15 March 2019 concerning tolpyralate, Opinion of 15 March 2019 concerning trinickel disulphide, Opinion of 13 June 2019 concerning azamethiphos, Opinion of 13 June 2019 concerning 2-phenoxyethanol, Opinion of 13 June 2019 concerning 2,2-dibromo-2-cyanoacetamide, Opinion of 13 June 2019 concerning 3-aminomethyl-3,5,5-trimethylcyclohexylamine, Opinion of 13 June 2019 concerning 6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol, Opinion of 13 June 2019 concerning diflufenican (ISO) N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide, Opinion of 13 June 2019 concerning imidacloprid (ISO); 1-(6-chloropyridin-3-ylmethyl)-N-nitroimidazolidin-2-ylidenamine, Opinion of 13 June 2019 concerning pyriofenone, Opinion of 13 June 2019 concerning S-abscisic acid, Opinion of 13 June 2019 concerning tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate, Opinion of 20 September 2019 concerning 1,2-epoxy-4-epoxyethylcyclohexane, Opinion of 20 September 2019 concerning 4-methylpentan-2-one, Opinion of 20 September 2019 concerning boric acid; diboron trioxide; tetraboron disodium heptaoxide hydrate; disodium tetraborate anhydrous; orthoboric acid sodium salt; disodium tetraborate decahydrate; disodium tetraborate pentahydrate, Opinion of 20 September 2019 concerning citric acid, Opinion of 20 September 2019 concerning clomazone, Opinion of 20 September 2019 concerning desmedipham, Opinion of 20 September 2019 concerning dimethomorph, Opinion of 20 September 2019 concerning emamectin benzoate, Opinion of 20 September 2019 concerning esfenvalerate (ISO) (S)-α-cyano-3-phenoxybenzyl (S)-2-(4-chlorophenyl)-3-methylbutyrate, Opinion of 20 September 2019 concerning ethametsulfuron-methyl (ISO), Opinion of 20 September 2019 concerning mecoprop-P (ISO); (R)-2-(4-chloro-2-methylphenoxy)propionic acid and its salts, Opinion of 20 September 2019 concerning methyl salicylate, Opinion of 20 September 2019 concerning phenmedipham (ISO), Opinion of 20 September 2019 concerning trifloxystrobin (ISO), Opinion of 20 September 2019 concerning triticonazole, Opinion of 5 December 2019 concerning 1,4-dimethylnaphthalene, Opinion of 5 December 2019 concerning (3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide, Opinion of 5 December 2019 concerning 3-methylpyrazole, Opinion of 5 December 2019 concerning carbendazim (ISO); methyl benzimidazol-2-ylcarbamate, Opinion of 5 December 2019 concerning cypermethrin cis/trans +/- 40/60; (RS)-α-cyano-3-phenoxybenzyl (1RS,3RS;1RS,3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate, Opinion of 5 December 2019 concerning imazamox (ISO); (RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid,

Opinion of 5 December 2019 concerning tetrafluoroethylene, Opinion of 5 December 2019 concerning thiamethoxam (ISO); 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine, Opinion of 5 December 2019 concerning trinexapac-ethyl (ISO); ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate. (3) Acute Toxicity Estimates (ATE) are mainly used to determine the classification for human health acute toxicity of mixtures containing substances classified for acute toxicity. The inclusion of harmonised ATE values in the entries listed in Annex VI to Regulation (EC) No 1272/2008 facilitates the harmonisation of the classification of mixtures and provides support for enforcement authorities. Following further scientific assessmentsof some substances, ATE values have been derived by the Agency for dicopper oxide, dicopper chloride trihydroxide, tetracopper hexahydroxide sulphate and tetracopper hexahydroxide sulphate hydrate, copper flakes (coated with aliphatic acid), copper(II) carbonate--copper(II) hydroxide (1:1), copper dihydroxide; copper(II) hydroxide, bordeaux mixture; reaction products of copper sulphate with calcium dihydroxide and copper sulphate pentahydrate, in addition to those proposed in the RAC opinions for other substances. Those ATE values should be inserted in the penultimate column of Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008. (4) Additional information was received by the Commission contesting the scientific assessment set out in the RAC opinions of 15 March 2019 concerning mancozeb, of 20 September 2019 concerning 4-methylpentan-2-one, and of 20 September 2019 concerning dimethomorph. That information was assessed by the Commission and was not found sufficient to cast doubts on the scientific analysis contained in the RAC opinions. (5) The Commission therefore considers appropriate to introduce, update or delete the harmonised classification and labelling of certain substances. (6) Regulation (EC) No 1272/2008 should therefore be amended accordingly. (7) Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or revised classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Such requirements may include those set out in point (f) of Article 22(1) of Regulation (EC) No 1907/2006 of the European Parliament and of the Council Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).

or those set out in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ L 167, 27.6.2012, p. 1). . Suppliers should, however, have the possibility to apply the new or updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of this Regulation and as of the date of entry into force to ensure a high level of protection of human health and of the environment and to provide sufficient flexibility to suppliers, HAS ADOPTED THIS REGULATION:

Article 1

Amendments to Regulation (EC) No 1272/2008 Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

Article 2

Entry into force and application This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union. It shall apply from 17 December 2022. By way of derogation from the second paragraph of this Article, substances and mixtures may be classified, labelled and packaged in accordance with this Regulation from its date of entry into force. This Regulation shall be binding in its entirety and directly applicable in all Member States. Done at Brussels, 11 March 2021. For the Commission The President Ursula von der Leyen

Annex

ANNEX In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows: (1) the following entries are inserted: Index NoChemical NameEC NoCAS NoClassificationLabellingSpecific Conc. Limits, M-factors and ATENotesHazard Class and Category Code(s)Hazard statement Code(s)Pictogram, Signal Word Code(s)Hazard statement Code(s)Suppl. Hazard statement Code(s)601-093-00-61,4-dimethylnaphthalene209-335-9571-58-4 Acute Tox. 4 Asp. Tox. 1 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 3 H302 H304 H319 H400 H412 GHS07 GHS08 GHS09 Dgr H302 H304 H319 H410 oral: ATE = 1300 mg/kg bw M = 1 601-094-00-1 1-isopropyl-4-methylbenzene; p-cymene 202-796-799-87-6 Flam. Liq. 3 Acute Tox. 3 Asp. Tox. 1 Aquatic Chronic 2 H226 H331 H304 H411 GHS02 GHS06 GHS08 GHS09 Dgr H226 H331 H304 H411 inhalation: ATE = 3 mg/l (vapours)601-095-00-7 p-mentha-1,3-diene; 1-isopropyl-4-methylcyclohexa-1,3-diene; alpha-terpinene 202-795-199-86-5 Flam. Liq. 3 Acute Tox. 4 Skin Sens. 1 Asp. Tox. 1 Aquatic Chronic 2 H226 H302 H317 H304 H411 GHS02 GHS07 GHS08 GHS09 Dgr H226 H302 H317 H304 H411 oral: ATE = 1680 mg/kg bw602-110-00-Xtetrafluoroethylene204-126-9116-14-3Carc. 1BH350 GHS08 Dgr H350604-095-00-5 6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol; [DBMC] 204-327-1119-47-1Repr. 1BH360F GHS08 Dgr H360F606-152-00-X(5-chloro-2-methoxy-4-methyl-3-pyridyl)(4,5,6-trimethoxy-o-tolyl)methanone; pyriofenone-688046-61-9 Carc. 2 Aquatic Chronic 1 H351 H410 GHS08 GHS09 Wng H351 H410 M = 1 607-747-00-72,2-dibromo-2-cyanoacetamide; [DBNPA]233-539-710222-01-2

Acute Tox. 2 Acute Tox. 3 STOT RE 1 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H330 H301 H372 (respiratory tract) (inhalation) H315 H318 H317 H400 H410 GHS06 GHS08 GHS05 GHS09 Dgr H330 H301 H372 (respiratory tract) (inhalation) H315 H318 H317 H410 inhalation: ATE = 0,24 mg/l (dusts or mists) oral: ATE = 118 mg/kg bw M = 1 M = 1 607-748-00-2 [S-(Z,E)]-5-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)-3-methylpenta-2,4-dienoic acid; S-abscisic acid 244-319-521293-29-8 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 1 607-749-00-8methyl salicylate204-317-7119-36-8 Repr. 2 Acute Tox. 4 Skin Sens. 1B Aquatic Chronic 3 H361d H302 H317 H412 GHS07 GHS08 Wng H361d H302 H317 H412 oral: ATE = 890 mg/kg bw607-750-00-3citric acid201-069-177-92-9 Eye Irrit. 2 STOT SE 3 H319 H335 GHS07 Wng H319 H335 607-751-00-9 ethametsulfuron-methyl (ISO); methyl 2-({[4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)benzoate -97780-06-8 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H319 H400 H410 GHS07 GHS09 Wng H319 H410 M = 1000 M = 100 607-752-00-4 trinexapac-ethyl (ISO); ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate -95266-40-3 STOT RE 2 Skin Sens. 1B Aquatic Chronic 1 H373 (gastrointestinal tract) H317 H410 GHS08 GHS07 GHS09 Wng H373 (gastrointestinal tract) H317 H410 M = 1 607-753-00-X(3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide-78821-43-9Aquatic Chronic 4H413H413607-754-00-5benzyl salicylate204-262-9118-58-1Skin Sens. 1BH317 GHS07 Wng H317607-755-00-0 (RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate; tolpyralate -1101132-67-5 Carc. 2 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H361fd H373 (eye) H400 H410 GHS08 GHS09 Wng H351 H361fd H373 (eye) H410 M = 10 M = 100 613-337-00-9 prothioconazole (ISO); 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione -178928-70-6 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 10 M = 1 613-338-00-4azamethiphos (ISO); S-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl] O,O-dimethyl thiophosphate252-626-035575-96-3 Carc. 2 Acute Tox. 3 Acute Tox. 4 STOT SE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H331 H302 H370 (nervous system) H317 H400 H410 GHS06 GHS08 GHS09 Dgr H351 H331 H302 H370 (nervous system) H317 H410 inhalation: ATE = 0,5 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 1000 M = 1000 613-339-00-X3-methylpyrazole215-925-71453-58-3 Repr. 1B Acute Tox. 4 STOT RE 2 Skin Corr. 1 Eye Dam. 1 H360D H302 H373 (lung) H314 H318 GHS08 GHS07 GHS05 Dgr H360D H302 H373 (lung) H314 oral: ATE = 500 mg/kg bw613-340-00-5clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one-81777-89-1 Acute Tox. 4 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H332 H302

H400 H410 GHS07 GHS09 Wng H332 H302 H410 inhalation: ATE = 4,85 mg/l (dusts or mists) oral: ATE = 768 mg/kg bw M = 1 M = 1 614-030-00-2emamectin benzoate (ISO); (4"R)-4"-deoxy-4"-(methylamino) avermectin B1 benzoate-155569-91-8 Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 STOT SE 1 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H331 H311 H301 H370 (nervous system) H372 (nervous system) H318 H400 H410 GHS06 GHS05 GHS08 GHS09 Dgr H331 H311 H301 H370 (nervous system) H372 (nervous system) H318 H410 inhalation: ATE = 0,663 mg/l (dusts or mists) dermal: ATE = 300 mg/kg bw oral: ATE = 60 mg/kg bw STOT RE 1; H372: C ≥ 5 %; STOT RE 2; H373: 0,5 % ≤ C < 5 % M = 10000 M = 10000 616-234-00-7N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen-1228284-64-7 Carc. 2 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H361f H400 H410 GHS08 GHS09 Wng H351 H361f H410 M = 1 M = 1 616-235-00-2N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane-874967-67-6 Carc. 2 Aquatic Acute 1 Aquatic Chronic 2 H351 H400 H411 GHS08 GHS09 Wng H351 H410 M = 1 (2) the entries corresponding to index numbers 005-007-00-2; 005-008-00-8; 005-011-00-4; 005-011-01-1; 005-011-02-9; 006-069-00-3; 006-076-00-1; 015-113-00-0; 028-007-00-4; 029-002-00-X; 029-015-00-0; 029-016-00-6; 029-017-00-1; 029-018-00-7; 029-019-01-X; 029-020-00-8; 029-021-00-3; 029-022-00-9; 029-023-00-4; 601-029-00-7; 601-096-00-2; 603-024-00-5; 603-066-00-4; 603-098-00-9; 606-004-00-4; 607-421-00-4; 607-424-00-0; 607-434-00-5; 608-058-00-4; 612-067-00-9; 612-252-00-4; 613-048-00-8; 613-102-00-0; 613-111-00-X; 613-166-00-X; 613-208-00-7; 613-267-00-9; 613-282-00-0; 616-032-00-9; 616-106-00-0 and 616-113-00-9 are replaced by the following entries respectively: Index NoChemical NameEC NoCAS NoClassificationLabellingSpecific Conc. Limits, M- factors and ATENotesHazard Class and Category Code(s)Hazard statement Code(s)Pictogram, Signal Word Code(s)Hazard statement Code(s)Suppl. Hazard statement Code(s)005-007-00-2 boric acid [1] boric acid [2] 233-139-2 [1] 234-343-4 [2] 10043-35-3 [1] 11113-50-1 [2] Repr. 1BH360FD GHS08 Dgr H360FD005-008-00-8diboron trioxide215-125-81303-86-2Repr. 1BH360FD GHS08 Dgr H360FD005-011-00-4 tetraboron disodium heptaoxide, hydrate; [1] disodium tetraborate, anhydrous; [2] orthoboric acid, sodium salt [3] disodium tetraborate decahydrate [4] disodium tetraborate pentahydrate [5] 235-541-3 [1] 215-540-4 [2] 237-560-2 [3] 215-540-4 [4] 215-540-4 [5] 12267-73-1 [1] 1330-43-4 [2] 13840-56-7 [3] 1303-96-4 [4] 12179-04-3 [5] Repr. 1BH360FD GHS08 Dgr H360FD 006-069-00-3 thiophanate-methyl (ISO); dimethyl (1,2-phenylenedicarbamothioyl)biscarbamate; dimethyl 4,4′-(o-phenylene)bis(3-thioallophanate) 245-740-723564-05-8 Carc. 2 Muta. 2 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H341 H332 H317 H400 H410 GHS08 GHS07 GHS09 Wng H351 H341 H332 H317 H410 inhalation: ATE = 1,7 mg/l

(dusts and mists) M = 10 M = 10 006-076-00-1mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt-8018-01-7 Carc. 2 Repr. 1B STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H360D H373 (thyroid, nervous system) H317 H400 H410 GHS08 GHS07 GHS09 Dgr H351 H360D H373 (thyroid, nervous system) H317 H410 M = 10 M = 10 015-113-00-0 tolclofos-methyl (ISO); O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate 260-515-357018-04-9 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410 M = 1 M = 1 028-007-00-4 trinickel disulfide; nickel subsulfide; [1] heazlewoodite [2] 234-829-6 [1]

• [2] 12035-72-2 [1] 12035-71-1 [2] Carc. 1A Muta. 2 Acute Tox. 3 STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H350i H341 H331 H372 H317 H400 H410 GHS08 GHS06 GHS09 Dgr H350i H341 H331 H372 H317 H410 inhalation: ATE = 0,92 mg/l (dusts or mists) 029-002-00-X dicopper oxide; copper (I) oxide 215-270-71317-39-1 Acute Tox. 4 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H332 H302 H318 H400 H410 GHS07 GHS05 GHS09 Dgr H332 H302 H318 H410 inhalation: ATE = 3,34 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 100 M = 10 029-015-00-0copper thiocyanate214-183-11111-67-7 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410EUH032 M = 10 M = 10 029-016-00-6copper(II) oxide215-269-11317-38-0 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 100 M = 10 029-017-00-1dicopper chloride trihydroxide215-572-91332-65-6 Acute Tox. 4 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 H332 H301 H400 H410 GHS06 GHS09 Dgr H332 H301 H410 inhalation: ATE = 2,83 mg/l (dusts or mists) oral: ATE = 299 mg/kg bw M = 10 M = 10 029-018-00-7 tetracopper hexahydroxide sulphate; [1] tetracopper hexahydroxide sulphate hydrate [2] 215-582-3 [1] 215-582-3 [2] 1333-22-8 [1] 12527-76-3 [2] Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 GHS09 Wng H302 H410 oral: ATE = 500 mg/kg bw M = 10 M = 10 029-019-01-Xcopper flakes (coated with aliphatic acid)-- Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 H302 H319 H400 H410 GHS06 GHS09 Dgr H331 H302 H319 H410 inhalation: ATE = 0,733 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 10 029-020-00-8copper(II) carbonate—copper(II) hydroxide (1:1)235-113-612069-69-1 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H332 H302 H319 H400 H410 GHS07 GHS09 Wng H332 H302 H319 H410 inhalation: ATE = 1,2 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 10 029-021-00-3 copper dihydroxide; copper(II) hydroxide 243-815-920427-59-2 Acute Tox. 2 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H330 H302 H318 H400 H410 GHS06 GHS05 GHS09 Dgr H330 H302 H318 H410 inhalation: ATE = 0,47 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 10 029-022-00-9 bordeaux mixture; reaction products of copper sulphate with calcium dihydroxide -8011-63-0 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1

Aquatic Chronic 1 H332 H318 H400 H410 GHS07 GHS05 GHS09 Dgr H332 H318 H410 inhalation: ATE = 1,97 mg/l (dusts or mists) M = 10 M = 1 029-023-00-4copper sulphate pentahydrate231-847-67758-99-8 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H302 H318 H400 H410 GHS07 GHS05 GHS09 Dgr H302 H318 H410 oral: ATE = 481 mg/kg bw M = 10 M = 1 601-029-00-7 dipentene; limonene [1] (S)-p-mentha-1,8-diene; l-limonene [2] trans-1-methyl-4-(1-methylvinyl)cyclohexene; [3] (±)-1-methyl-4-(1-methylvinyl)cyclohexene [4] 205-341-0 [1] 227-815-6 [2] 229-977-3 [3] 231-732-0 [4] 138-86-3 [1] 5989-54-8 [2] 6876-12-6 [3] 7705-14-8 [4] Flam. Liq. 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H226 H315 H317 H400 H410 GHS02 GHS07 GHS09 Wng H226 H315 H317 H410 C601-096-00-2 (R)-p-mentha-1,8-diene; d-limonene 227-813-55989-27-5 Flam. Liq. 3 Skin Irrit. 2 Skin Sens. 1B Asp. Tox. 1 Aquatic Acute 1 Aquatic Chronic 3 H226 H315 H317 H304 H400 H412 GHS02 GHS07 GHS08 GHS09 Dgr H226 H315 H317 H304 H410 M = 1603-024-00-51,4-dioxane204-661-8123-91-1 Flam. Liq. 2 Carc. 1B STOT SE 3 Eye Irrit. 2 H225 H350 H335 H319 GHS02 GHS08 GHS07 Dgr H225 H350 H335 H319 EUH019 EUH066 D 603-066-00-47-oxa-3-oxiranylbicyclo[4.1.0]heptane; 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide203-437-7106-87-6 Carc. 1B Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 H350 H341 H360F H331 H302 GHS08 GHS06 Dgr H350 H341 H360F H331 H302 inhalation: ATE = 0,5 mg/l (dusts or mists) oral: ATE = 1847 mg/kg bw 603-098-00-92-phenoxyethanol204-589-7122-99-6 Acute Tox. 4 STOT SE 3 Eye Dam. 1 H302 H335 H318 GHS05 GHS07 Dgr H302 H335 H318 oral: ATE = 1394 mg/kg bw 606-004-00-44-methylpentan-2-one; isobutyl methyl ketone203-550-1108-10-1 Flam. Liq. 2 Carc. 2 Acute Tox. 4 STOT SE 3 Eye Irrit. 2 H225 H351 H332 H336 H319 GHS02 GHS07 GHS08 Dgr H225 H351 H332 H336 H319 EUH066inhalation: ATE = 11 mg/l (vapours)607-421-00-4 cypermethrin (ISO); α-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; cypermethrin cis/trans +/- 40/60 257-842-952315-07-8 Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H332 H302 H335 H373 (nervous system) H400 H410 GHS07 GHS08 GHS09 Wng H332 H302 H335 H373 (nervous system) H410 oral; ATE = 500 mg/kg bw inhalation; ATE = 3,3 mg/l (dusts or mists) M = 100000 M = 100000 607-424-00-0trifloxystrobin (ISO); methyl (E)-methoxyimino-{(E)-α-[1-(α,α,α-trifluoro-m-tolyl)ethylideneaminooxy]-o-tolyl}acetate-141517-21-7 Lact. Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H362 H317 H400 H410 GHS07 GHS09 Wng H362 H317 H410 M = 100 M = 10 607-434-00-5 mecoprop-P (ISO) [1] and its salts; (R)-2-(4-chloro-2-methylphenoxy)propionic acid [1] and its salts 240-539-0 [1]16484-77-8 [1] Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H302 H318 H400 H410 GHS07 GHS05 GHS09 Dgr H302 H318 H410 oral: ATE = 431 mg/kg bw M = 10 M = 10 608-058-00-4 esfenvalerate (ISO); (S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate

-66230-04-4 Acute Tox. 3 Acute Tox. 3 STOT SE 1 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H331 H301 H370 (nervous system) H373 H317 H400 H410 GHS06 GHS08 GHS09 Dgr H331 H301 H370 (nervous system) H373 H317 H410 oral; ATE = 88,5 mg/kg bw inhalation; ATE = 0,53 mg/l (dusts or mists) M = 10000 M = 10000 612-067-00-93-aminomethyl-3,5,5-trimethylcyclohexylamine220-666-82855-13-2 Acute Tox. 4 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1A H302 H314 H318 H317 GHS05 GHS07 Dgr H302 H314 H317 oral: ATE = 1030 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,001 % 612-252-00-4 imidacloprid (ISO); (E)-1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolidin-2-ylideneamine; (2E)-1-[(6-chloropyridin-3-yl) methyl]-N-nitroimidazolidin-2-imine 428-040-8138261-41-3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 H301 H400 H410 GHS06 GHS09 Dgr H301 H410 oral: ATE = 131 mg/kg bw M = 100 M = 1000 613-048-00-8carbendazim (ISO); methyl benzimidazol-2-ylcarbamate234-232-010605-21-7 Muta. 1B Repr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H340 H360FD H317 H400 H410 GHS07 GHS08 GHS09 Dgr H340 H360FD H317 H410 M = 10 M = 10 613-102-00-0dimethomorph (ISO); (E,Z)-4-(3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)acryloyl)morpholine404-200-2110488-70-5 Repr. 1B Aquatic Chronic 2 H360F H411 GHS08 GHS09 Dgr H360F H411 613-111-00-X1,2,4-triazole206-022-9288-88-0 Repr. 1B Acute Tox. 4 Eye Irrit. 2 H360FD H302 H319 GHS08 GHS07 Dgr H360FD H302 H319 oral: ATE = 1320 mg/kg bw613-166-00-X flumioxazin (ISO); N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)cyclohex-1-ene-1,2-dicarboximide -103361-09-7 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 H361d H400 H410 GHS08 GHS09 Wng H361d H410 M = 1000 M = 1000 613-208-00-7 imazamox (ISO); (RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid -114311-32-9 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 H361d H400 H410 GHS08 GHS09 Wng H361d H410 M = 10 M = 10 613-267-00-9 thiamethoxam (ISO); 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine 428-650-4153719-23-4 Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H361fd H302 H400 H410 GHS07 GHS08 GHS09 Wng H361fd H302 H410 oral: ATE = 780 mg/kg bw M = 10 M = 10 613-282-00-0 triticonazole (ISO); (RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol -138182-18-0 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361f H373 H400 H410 GHS08 GHS09 Wng H361f H373 H410 M = 1 M = 1 616-032-00-9 diflufenican (ISO); N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide; 2′,4′-difluoro-2-(α,α,α-trifluoro-m-tolyloxy) nicotinanilide -83164-33-4 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 10000 M = 1000 616-106-00-0phenmedipham (ISO); methyl 3-(3-methylcarbaniloyloxy)carbanilate237-199-013684-63-4 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 10 M = 10 616-113-00-9 desmedipham (ISO); ethyl 3-phenylcarbamoyloxyphenylcarbamate 237-198-513684-56-5 Repr. 2 Aquatic Acute 1

Aquatic Chronic 1 H361d H400 H410 GHS08 GHS09 Wng H361d H410 M = 10 M = 10 (3) the entry corresponding to index number 015-192-00-1 is deleted.